Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3B-FOLFOX in MSS Metastatic Colorectal Cancer
NCT05627635Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2023
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in colorectal cancer (CRC), sponsored by City of Hope. Started May 2023; status: active, not recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05627635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627635.